| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7235567 | XSPIRE PHARMA | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
Jun, 2021
(2 years ago) | |
| US7713999 | XSPIRE PHARMA | Thrombin receptor antagonists |
May, 2024
(a month from now) | |
| US7304078 | XSPIRE PHARMA | Thrombin receptor antagonists |
Dec, 2027
(3 years from now) | |
Zontivity is owned by Xspire Pharma.
Zontivity contains Vorapaxar Sulfate.
Zontivity has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Zontivity are:
- US7235567
Zontivity was authorised for market use on 08 May, 2014.
Zontivity is available in tablet;oral dosage forms.
Zontivity can be used as reduction of thrombotic cardiovascular events, reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad).
Drug patent challenges can be filed against Zontivity from 08 May, 2018.
The generics of Zontivity are possible to be released after 23 December, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2019 |
Drugs and Companies using VORAPAXAR SULFATE ingredient
NCE-1 date: 08 May, 2018
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad); Reduction of thrombotic cardiovascular events
Dosage: TABLET;ORAL
ZONTIVITY family patents
